KyungdongPharm Logo

KyungdongPharm

Develops and manufactures prescription drugs, OTC products, and pharmaceutical ingredients.

011040 | KO

Overview

Corporate Details

ISIN(s):
KR7011040003
LEI:
Country:
South Korea
Address:
경기도 화성시 양감면 제약단지로 224-3, 화성시

Description

KyungdongPharm is a pharmaceutical company engaged in the development, manufacturing, and distribution of medicines. Since its establishment in 1975, the company has focused on producing a broad portfolio of specialized therapeutic drugs and general pharmaceuticals. Its product lines encompass prescription medicines, with a focus on areas such as liver therapy, and over-the-counter products, including its prominent painkiller brand, 'Geunal-N'. The company also manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. Utilizing advanced production facilities and proprietary technology, KyungdongPharm is dedicated to developing high-quality medicines supported by clinical research to contribute to public health.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-16 00:00
주요사항보고서(교환사채권발행결정)
Korean 128.3 KB
2025-12-16 00:00
주요사항보고서(자기주식처분결정)
Korean 118.9 KB
2025-09-10 00:00
자기주식처분결과보고서
Korean 16.9 KB
2025-09-01 00:00
주요사항보고서(자기주식처분결정)
Korean 29.7 KB
2025-08-27 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 30.0 KB
2025-08-27 00:00
주식등의대량보유상황보고서(일반)
Korean 250.7 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-12 00:00
주식등의대량보유상황보고서(일반)
Korean 265.3 KB
2025-07-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-05-14 00:00
분기보고서 (2025.03)
Korean 1.5 MB
2025-05-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-04-16 00:00
주식등의대량보유상황보고서(일반)
Korean 261.5 KB
2025-04-15 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.6 KB
2025-03-28 00:00
정기주주총회결과
Korean 22.4 KB
2025-03-20 00:00
감사보고서제출
Korean 25.7 KB

Automate Your Workflow. Get a real-time feed of all KyungdongPharm filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KyungdongPharm

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KyungdongPharm via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures biologic medicines, including biosimilars and novel drugs.
South Korea
007460
Develops drugs for intractable diseases by regulating oxidative stress and CAFs.
South Korea
293780
Aptamer Sciences Inc Logo
Clinical-stage company developing aptamer-based therapeutics for oncology.
South Korea
291650
Aptorum Group Ltd Logo
Clinical-stage biopharma developing therapeutics for oncology and infectious diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Pharmaceutical company developing oral film medicines for CNS and allergic reactions.
United States of America
AQST
Arbutus Biopharma Corp Logo
Clinical-stage biopharma company developing a functional cure for chronic Hepatitis B.
United States of America
ABUS
Arcellx, Inc. Logo
A clinical-stage biotech company developing immunotherapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharmaceutical and nutraceutical products from marine membrane lipids.
Norway
ABS
ArcticZymes Technologies Logo
Develops and manufactures novel recombinant enzymes from Arctic marine organisms.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
A commercial-stage mRNA medicines company focused on rare and infectious diseases.
United States of America
ARCT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.